

Katie Stone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7941424/publications.pdf>

Version: 2024-02-01

18
papers

542
citations

1307594

7
h-index

1125743

13
g-index

18
all docs

18
docs citations

18
times ranked

732
citing authors

#	ARTICLE	IF	CITATIONS
1	Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS ONE, 2019, 14, e0218660.	2.5	22
2	Storming the Castle with TCP. Blood, 2019, 133, 1697-1698.	1.4	1
3	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockadeâ€“refractory idiopathic multicentric Castleman disease. Journal of Clinical Investigation, 2019, 129, 4451-4463.	8.2	87
4	Plasma proteomics identifies a â€“chemokine stormâ€™™ in idiopathic multicentric Castleman disease. American Journal of Hematology, 2018, 93, 902-912.	4.1	63
5	Daratumumab for POEMS Syndrome. Mayo Clinic Proceedings, 2018, 93, 542-544.	3.0	26
6	Treatment of Idiopathic Castleman Disease. Hematology/Oncology Clinics of North America, 2018, 32, 89-106.	2.2	49
7	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018, 132, 2115-2124.	1.4	232
8	Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center. Blood, 2018, 132, 3701-3701.	1.4	1
9	Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization. Blood, 2018, 132, 2415-2415.	1.4	1
10	Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity. Blood, 2018, 132, 4468-4468.	1.4	0
11	Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma. Blood, 2018, 132, 4466-4466.	1.4	0
12	Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma. Blood, 2015, 126, 2990-2990.	1.4	0
13	Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels. PLoS ONE, 2013, 8, e54610.	2.5	44
14	Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity. Blood, 2013, 122, 5389-5389.	1.4	0
15	Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients. Blood, 2012, 120, 579-579.	1.4	2
16	Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms. Blood, 2012, 120, 4020-4020.	1.4	0
17	Prognostic Significance of DNA/Cig Flow Cytometry Assay in the â€“eraâ€“of Novel Therapies in Multiple Myeloma (MM).. Blood, 2012, 120, 2918-2918.	1.4	6
18	Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma. Blood, 2011, 118, 2918-2918.	1.4	8